Figure 8. Influence of combinations of checkpoint abrogators on the cytotoxic activities of trabectedin and lurbinectedin toward ovarian cancer cell lines.

A. IGROV1 cells were first exposed for 1 hour to either no drug (black diamond), 2 μM KU-60019 (white triangle), 1 μM VE-821 (white square) or a combination of 2 μM KU-60019 and 1 μM VE-821 (white circle) before addition of either trabectedin (left panel) or lurbinectedin (right panel) at the indicated concentrations. The combination of 2 μM KU-600019 and 1 μM VE-821 had a minor effect (<IC₂₀) on IGROV1 cells while 2 μM KU-600019 or 1 μM VE-821 alone had no toxicities. B. A2780 cells were first exposed for 1 hour to either no drug (black diamond), 2 μM KU-60019 (white triangle), 1 μM VE-821 (white square) or a combination of 2 μM KU-60019 and 1 μM VE-821 (white circle) before addition of either trabectedin (left panel) or lurbinectedin (right panel) at the indicated concentrations. The combination of 2 μM KU-600019 and 1 μM VE-821 as well as 2 μM KU-600019 or 1 μM VE-821 alone have no toxicity toward A2780 cells. C. A2780/CP70 cells were first exposed for 1 hour to either no drug (black diamond), 1 μM KU-60019 (white triangle), 1 μM VE-821 (white square) or 1 μM KU-60019 in combination with 1 μM VE-821 (white circle) before addition of either trabectedin (left panel) or lurbinectedin (right panel) at the indicated concentrations. The combination of 1 μM KU-600019 and 1 μM VE-821 has a minor effect (<IC₂₀) on A2780/CP cells growth while either 1 μM KU-600019 or 1 μM VE-821 alone have no toxicities. SDs are indicated by error bars and are indicated when they exceed symbol size.